Ba/F3 cells and their use in kinase drug discovery
The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Purpose of review Due to their ability to function as dominant oncogenes, protein kinases have become favored targets in the quest for 'molecularly-targeted' cancer chemotherapeutics. The discovery of a large number of cancer-associated mutations in the kinome, and the progress in developing specific small-molecule kinase inhibitors has increased the need for accurate, reproducible, and efficient kinase activity-dependent cellular assay systems. Recent findings Ba/F3, a murine interleukin-3 dependent pro-B cell line is increasingly popular as a model system for assessing both the potency and downstream signaling of kinase oncogenes, and the ability of small-molecule kinase inhibitors to block kinase activity. Facilitated by their growth properties, Ba/F3 cells have recently been adapted to high-throughput assay formats for compound profiling. Further, several published approaches show promise in predicting resistance to small-molecule kinase inhibitors elicited by point mutations interfering with inhibitor binding. Summary Ba/F3 cells are an increasingly popular tool in kinase drug discovery. The ability to test the transforming capacity of newly identified kinase mutations, and to profile drug candidates and compound libraries in high-throughput fashion, combined with the use of Ba/F3 cells to predict clinical resistance will greatly facilitate developments in this field.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Cited by
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Acquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
Schoepfer, J., Jahnke, W., Berellini, G., Buonamici, S., Cotesta, S., Cowan-Jacob, S. W., Dodd, S., Drueckes, P., Fabbro, D., Gabriel, T., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01040 · Cited by 454
Self-citationIn vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
Parmentier, J. M., Voss, J., Graff, C., Schwartz, A., Argiriadi, M., Friedman, M., Camp, H. S., Padley, R. J., George, J. S., Hyland, D., et al. (2018) · BMC Rheumatology · doi:10.1186/s41927-018-0031-x · Cited by 390
Ten things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Moebitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 347
“…methods such as Western blots, phospho-ELISAs, reverse phase arrays, ALPHA (amplified luminescent proximity homogeneous assay)-screen assay and high content cellular analysis, and are being offered by various providers (Chen et al., 2005; Warmuth et al., 2007; Eglen et al., 2008; Jia et al., 2008).”
MethodOncogenic ERBB3 mutations in human cancers.
Jaiswal, B. S., Kljavin, N. M., Stawiski, E. W., Chan, E., Parikh, C., Durinck, S., Chaudhuri, S., Pujara, K., Guillory, J., Edgar, K. A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.012 · Cited by 350
“ERBB3 Mutants Promote Interleukin-3-Independent Cell Survival and Transformation BaF3 is an interleukin (IL)-3 dependent pro-B cell line that has been widely used to study oncogenic activity of genes and development of drugs that target oncogenic drivers (Lee et al., 2006; Warmuth et al., 2007).”
BackgroundSystematic Functional Annotation of Somatic Mutations in Cancer
Ng, P. K.-S., Li, J., Jeong, K. J., Shao, S., Chen, H., Tsang, Y. H., Sengupta, S., Wang, Z., Bhavana, V. H., Tran, R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.021 · Cited by 335
Selectively Nonselective Kinase Inhibition: Striking the Right Balance
Morphy, R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901132v · Cited by 292
Sievert, A. J., Lang, S.-S., Boucher, K. L., Madsen, P. J., Slaunwhite, E., Choudhari, N., Kellet, M., Storm, P. B., & Resnick, A. C. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219232110 · Cited by 285
“Ba/F3 cells require IL-3 for growth, but this dependence can be overcome by constitutive MAPK activation (11).”
BackgroundCASK Functions as a Mg2+-independent neurexin kinase
Mukherjee, K., Sharma, M., Urlaub, H., Bourenkov, G. P., Jahn, R., Südhof, T. C., & Wahl, M. C. (2008) · Cell · doi:10.1016/j.cell.2008.02.036 · Cited by 271
Eight-channel iTRAQ Enables Comparison of the Activity of Six Leukemogenic Tyrosine Kinases
Pierce, A., Unwin, R. D., Evans, C. A., Griffiths, S., Carney, L., Zhang, L., Jaworska, E., Lee, C.-F., Blinco, D., Okoniewski, M. J., et al. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m700251-mcp200 · Cited by 255
“Ba/F3 cells are commonly used in studies on leukemogenesis and are therefore suitable for initial analyses (36).”
BackgroundRobichaux, J. P., Elamin, Y. Y., Vijayan, R. S. K., Nilsson, M. B., Hu, L., He, J., Zhang, F., Pisegna, M., Poteete, A., Sun, H., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.001 · Cited by 242
Liang, H., Cheung, L. W. T., Li, J., Ju, Z., Yu, S., Stemke-Hale, K., Dogruluk, T., Lu, Y., Liu, X., Gu, C., et al. (2012) · Genome Research · doi:10.1101/gr.137596.112 · Cited by 241
The genomic landscape of pediatric myelodysplastic syndromes
Schwartz, J. R., Ma, J., Lamprecht, T., Walsh, M., Wang, S., Bryant, V., Song, G., Wu, G., Easton, J., Kesserwan, C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01590-5 · Cited by 210
Gain-of-Function Mutations in the Extracellular Domain of KIT Are Common in Canine Mast Cell Tumors
Letard, S., Yang, Y., Hanssens, K., Palmérini, F., Leventhal, P. S., Guéry, S., Moussy, A., Kinet, J.-P., Hermine, O., & Dubreuil, P. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0067 · Cited by 185
“characterizing protein tyrosine kinases and for the discovery of tyrosine kinase inhibitors (14).”
BackgroundMechanisms of drug resistance in kinases
Barouch-Bentov, R., & Sauer, K. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.546344 · Cited by 181
“Preclinical studies have unveiled drug resistance mechanisms for many additional kinases [28-33].”
BackgroundTan, L., Wang, J., Tanizaki, J., Huang, Z., Aref, A. R., Rusan, M., Zhu, S.-J., Zhang, Y., Ercan, D., Liao, R. G., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403438111 · Cited by 174
“Ba/F3 cells are a murine pre-B cell that can be transformed readily with activated kinases to allow growth in the absence of IL-3 and frequently are used to evaluate the activity of compounds against kinases of interest in a cellular context (56).”
BackgroundDrilon, A., Somwar, R., Wagner, J. P., Vellore, N. A., Eide, C. A., Zabriskie, M. S., Arcila, M. E., Hechtman, J. F., Wang, L., Smith, R. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2013 · Cited by 166
“Ba/F3 cells are an IL3-dependent pro-B murine cell line that is a well-established model system for eliciting oncogene addiction and testing kinase inhibitor efficacy (24).”
BackgroundTang, J., Tanoli, Z.-U.-R., Ravikumar, B., Alam, Z., Rebane, A., Vähä-Koskela, M., Peddinti, G., van Adrichem, A. J., Wakkinen, J., Jaiswal, A., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.11.009 · Cited by 154
Jang, J., To, C., De Clercq, D. J. H., Park, E., Ponthier, C. M., Shin, B. H., Mushajiang, M., Nowak, R. P., Fischer, E. S., Eck, M. J., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202003500 · Cited by 139
Manley, P. W., Barys, L., & Cowan-Jacob, S. W. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106458 · Cited by 146
EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
He, M., Capelletti, M., Nafa, K., Yun, C.-H., Arcila, M. E., Miller, V. A., Ginsberg, M. S., Zhao, B., Kris, M. G., Eck, M. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2361 · Cited by 149
“Transfection of Ba/F3 cells with mutant EGFR constructs harboring two different insertions in exon 19 (I744_K745insKIPVAI and K745_E746insTPVAIK) resulted in IL3 independent growth, indicating that these mutations were oncogenic (29).”
Atak, Z. K., Gianfelici, V., Hulselmans, G. J., Keersmaecker, K. D., Devasia, A. G., Geerdens, E., Mentens, N., Chiaretti, S., Durinck, K., Uyttebroeck, A., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003997 · Cited by 161
“To assess whether the TPM3-JAK2 and SSBP2-FER fusions encode oncogenic proteins, we tested their transforming properties in the IL-3–dependent Ba/F3 cell line [55].”
BackgroundDisruption of PH–kinase domain interactions leads to oncogenic activation of AKT in human cancers
Parikh, C., Janakiraman, V., Wu, W.-I., Foo, C. K., Kljavin, N. M., Chaudhuri, S., Stawiski, E., Lee, B., Lin, J., Li, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204384109 · Cited by 144
“The BaF3 pro-B cells can be rendered growth factor-independent by enforced expression of oncogenes (18).”
BackgroundByron, S. A., Chen, H., Wortmann, A., Loch, D., Gartside, M. G., Dehkhoda, F., Blais, S. P., Neubert, T. A., Mohammadi, M., & Pollock, P. M. (2013) · Neoplasia · doi:10.1593/neo.121106 · Cited by 138
Development of Selective Covalent Janus Kinase 3 Inhibitors
Tan, L., Akahane, K., McNally, R., Reyskens, K. M. S. E., Ficarro, S. B., Liu, S., Herter-Sprie, G. S., Koyama, S., Pattison, M. J., Labella, K., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00710 · Cited by 122
Fairhurst, R. A., Knöpfel, T. F., Buschmann, N., Leblanc, C., Mah, R., Todorov, M., Nimsgern, P., Ripoche, S., Niklaus, M., Warin, N., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01019 · Cited by 123
Coffey, G., DeGuzman, F. R., Inagaki, M., Pak, Y., Delaney, S. M., Ives, D. J., Betz, A., Jia, Z. J., Pandey, A., Baker, D. C., et al. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.188441 · Cited by 120
“The six lines tested were transformed to proliferate independently of interleukin-3 by stable expression of JAK1, JAK2, JAK3, Tyk2, Syk, or Zap70 kinase domains fused to the translocated ETS leukemia (TEL) transcription factor (Warmuth et al., 2007).”
BackgroundAyaz, P., Lyczek, A., Paung, Y., Mingione, V. R., Iacob, R. E., de Waal, P. W., Engen, J. R., Seeliger, M. A., Shan, Y., & Shaw, D. E. (2023) · Nature Communications · doi:10.1038/s41467-023-36956-5 · Cited by 102
Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases
Sheetz, J. B., Mathea, S., Karvonen, H., Malhotra, K., Chatterjee, D., Niininen, W., Perttilä, R., Preuss, F., Suresh, K., Stayrook, S. E., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.06.018 · Cited by 105
“Even if modulation of the properties of the pseudokinase domain by small molecules proves insufficient to block pseudokinase function, the ligands developed for the ATP-binding site of these proteins could instead be used for developing proteolysis targeting chimeras (PROTACs), as reported for both kinase-active RTKs…”
MethodInfluentialReckel, S., Hamelin, R., Georgeon, S., Armand, F., Jolliet, Q., Chiappe, D., Moniatte, M., & Hantschel, O. D. (2017) · Leukemia · doi:10.1038/leu.2017.36 · Cited by 107
Engineering an inhibitor-resistant human CSF1R variant for microglia replacement
Chadarevian, J. P., Lombroso, S. I., Peet, G. C., Hasselmann, J., Tu, C., Marzan, D. E., Capocchi, J., Purnell, F. S., Nemec, K. M., Lahian, A., et al. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20220857 · Cited by 95
“Ba/F3s are widely and successfully used to study human kinase mutations (Warmuth et al., 2007; Smith et al., 2012) and can be switched from IL-3 to CSF1 dependence following CSF1R transduction (Fig.”
PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia
Kleppe, M., Soulier, J., Asnafi, V., Mentens, N., Hornakova, T., Knoops, L., Constantinescu, S., Sigaux, F., Meijerink, J. P., Vandenberghe, P., et al. (2011) · Blood · doi:10.1182/blood-2010-10-314286 · Cited by 98
Tumor Suppression by Phospholipase C-β3 via SHP-1-Mediated Dephosphorylation of Stat5
Xiao, W., Hong, H., Kawakami, Y., Kato, Y., Wu, D., Yasudo, H., Kimura, A., Kubagawa, H., Bertoli, L. F., Davis, R. S., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.05.018 · Cited by 88
“IL-3-dependent mouse Ba/F3 cells have been extensively used to investigate Stat5-related signaling events (Warmuth et al., 2007).”
Guan, J., Tucker, E. R., Wan, H., Chand, D., Danielson, L. S., Ruuth, K., Wakil, A. E., Witek, B., Jamin, Y., Umapathy, G., et al. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.024448 · Cited by 94
“Ba/F3 cells are able to overcome IL-3 dependence, allowing them to survive and proliferate in the absence of IL-3 while expressing constitutively active tyrosine kinases or other oncogenes; characteristics that are often exploited in kinase drug discovery (Warmuth et al., 2007).”
Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D
Zheng, Q., Zhang, Z., Guiley, K. Z., & Shokat, K. M. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01565-w · Cited by 88
Chong, C. R., Bahcall, M., Capelletti, M., Kosaka, T., Ercan, D., Sim, T., Sholl, L. M., Nishino, M., Johnson, B. E., Gray, N. S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1601 · Cited by 84
“Ba/F3 cells have been extensively used in kinase drug discovery, including screens for compounds targeting kinases activated by rearrangement, such as ROS1 (12, 20, 21).”
Liu, Y. A., Jin, Q., Zou, Y., Ding, Q., Yan, S., Wang, Z., Hao, X., Nguyen, B., Zhang, X., Pan, J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01624 · Cited by 81
A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl
Choi, H. G., Ren, P., Adrián, F., Sun, F., Lee, H. S., Wang, X., Ding, Q., Zhang, G., Xie, Y., Zhang, J., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901808w · Cited by 74
Self-citationThe CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer
Izumi, H., Matsumoto, S., Liu, J., Tanaka, K., Mori, S., Hayashi, K., Kumagai, S., Shibata, Y., Hayashida, T., Watanabe, K., et al. (2021) · Nature · doi:10.1038/s41586-021-04135-5 · Cited by 76
Lyczek, A., Berger, B.-T., Rangwala, A. M., Paung, Y., Tom, J., Philipose, H., Guo, J., Albanese, S. K., Robers, M. B., Knapp, S., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111451118 · Cited by 68
Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia
Roskoski, R. J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106156 · Cited by 70
Breen, M. E., & Soellner, M. B. (2014) · ACS Chemical Biology · doi:10.1021/cb5008376 · Cited by 66
NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors
Somwar, R., Hofmann, N. E., Smith, B. D., Odintsov, I., Vojnic, M., Linkov, I., Tam, A., Khodos, I., Mattar, M. S., de Stanchina, E., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01508-w · Cited by 70
Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)
Heppner, D. E., Wittlinger, F., Beyett, T. S., Shaurova, T., Urul, D. A., Buckley, B., Pham, C. D., Schaeffner, I. K., Yang, B., Ogboo, B. C., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00213 · Cited by 64
Resistance to vemurafenib resulting from a novel mutation in the BRAFV 600 E kinase domain
Wagenaar, T. R., Ma, L., Roscoe, B., Park, S. M., Bolon, D. N., & Green, M. R. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12171 · Cited by 59
“…all relevant single mutants (because of sampling limitations and biases in random mutagenesis), or (ii) directed mutagenesis based on results from related targets (e.g., gatekeeper mutations in protein kinases) that do not broadly sample sequence space (reviewed in Warmuth et al., 2007).”
BackgroundCellular model system to dissect the isoform-selectivity of Akt inhibitors
Quambusch, L., Depta, L., Landel, I., Lubeck, M., Kirschner, T., Nabert, J., Uhlenbrock, N., Weisner, J., Kostka, M., Levy, L. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25512-8 · Cited by 62
Chand, D., Yamazaki, Y., Ruuth, K., Schönherr, C., Martinsson, T., Kogner, P., Attiyeh, E. F., Maris, J. M., Morozova, O., Marra, M. A., et al. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.010348 · Cited by 63
Trident cold atmospheric plasma blocks three cancer survival pathways to overcome therapy resistance
Guo, B., Pomicter, A. D., Li, F., Bhatt, S., Chen, C., Li, W., Qi, M., Huang, C., Deininger, M. W., Kong, M. G., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107220118 · Cited by 56
Discovery of a Selective Irreversible BMX Inhibitor for Prostate Cancer
Liu, F., Zhang, X., Weisberg, E., Chen, S., Hur, W., Wu, H., Zhao, Z., Wang, W., Mao, M., Cai, C., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb4000629 · Cited by 52
Davare, M. A., Henderson, J. J., Agarwal, A., Wagner, J. P., Iyer, S. R., Shah, N., Woltjer, R. L., Somwar, R., Gilheeney, S. W., DeCarvalo, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1052 · Cited by 57
“GOPC–ROS1 and CEP85L–ROS1 are dominant, targetable oncogenic drivers To test the oncogenic potential of the ROS1 fusions, we first used the Ba/F3 cytokine-independent transformation assay system (37).”
Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions
Gao, Y., Jiang, B., Kim, H., Berberich, M. J., Che, J., Donovan, K. A., Hatcher, J. M., Huerta, F., Kwiatkowski, N. P., Liu, Y., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01864 · Cited by 46
Discovery of a potent dual ALK and EGFR T790M inhibitor
Jang, J., Son, J. B., To, C., Bahcall, M., Kim, S. Y., Kang, S. Y., Mushajiang, M., Lee, Y., Janne, P. A., Choi, H. G., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.079 · Cited by 53
Self-citationA Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis
Bold, G., Schnell, C., Furet, P., McSheehy, P. M. J., Brüggen, J., Mestan, J., Manley, P. W., Drückes, P., Burglin, M., Dürler, U., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01582 · Cited by 50
c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors
Liu, H., Ai, J., Shen, A., Chen, Y., Wang, X., Xia, P., Chen, H., Shen, Y., Huang, M., Ding, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2448 · Cited by 46
“For further confirmation, we generated "gain-of-FGFR-addiction" cell lines using mouse pro-B BaF3 cells, a cell line known to intrinsically depend on IL3 for survival, and introduction of oncogenic kinase enables cell growth independent of IL3 (30, 31).”
BackgroundDiscovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma
Davis, L. E., Nusser, K. D., Przybył, J., Pittsenbarger, J., Hofmann, N. E., Varma, S., Vennam, S., Dêbiec‐Rychter, M., van de Rijn, M., & Davare, M. A. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1075 · Cited by 47
“KANK2-ALK is a transforming oncogenic driver in Ba/F3 cells Ba/F3, a pro-B murine cell line, is an established model system for investigating transformative potential of oncogenic kinase variants (42).”
BackgroundAvadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies
Renneville, A., Gasser, J. A., Grinshpun, D. E., Jean Beltran, P. M., Udeshi, N. D., Matyskiela, M. E., Clayton, T., McConkey, M., Viswanathan, K., Tepper, A., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0105 · Cited by 48
“Like other tyrosine kinase oncogenes (29), ZMYM2–FGFR1 transforms Ba/F3 cells to IL3 independence (30, 31), thereby rendering Ba/F3 cells dependent on the fusion oncoprotein for their survival and proliferation.”
Shao, W., Mishina, Y. M., Feng, Y., Caponigro, G., Cooke, V. G., Rivera, S., Wang, Y., Shen, F., Korn, J. M., Mathews Griner, L. A., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2033 · Cited by 44
Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors
Keddy, C., Shinde, P., Jones, K. L., Kaech, S., Somwar, R., Shinde, U. P., & Davare, M. A. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0395 · Cited by 45
“Ba/F3 is a well-established model system to interrogate drug efficacy and mechanisms of resistance (20, 22, 23, 25, 37).”
BackgroundDiscovery of Potent and Highly Selective Thienopyridine Janus Kinase 2 Inhibitors
Schenkel, L. B., Huang, X., Cheng, A. C., Deak, H. L., Doherty, E. M., Emkey, R., Gu, Y., Günaydin, H., Kim, J. L., Lee, J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200911r · Cited by 44
Burg, D. W., Yamamoto, M., Namekata, M., Haklani, J., Koike, K., & Halasz, M. (2017) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s123401 · Cited by 43
Lu, H., Villafañe, N., Dogruluk, T., Grzeskowiak, C. L., Kong, K., Tsang, Y. H., Zagorodna, O., Pantazi, A., Yang, L., Neill, N. J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2745 · Cited by 42
Analyzing Somatic Genome Rearrangements in Human Cancers by Using Whole-Exome Sequencing
Yang, L., Lee, M.-S., Lu, H., Oh, D., Kim, Y. J., Park, D., Park, G., Ren, X., Bristow, C. A., Haseley, P. S., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.03.017 · Cited by 41
Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms
Joshi, S. K., Qian, K., Bisson, W. H., Watanabe‐Smith, K., Huang, A., Bottomly, D., Traer, E. A., Tyner, J. W., McWeeney, S. K., Davare, M. A., et al. (2020) · Blood · doi:10.1182/blood.2019003691 · Cited by 41
Drápalová, E., Michlovská, L., Poštulková, H., Chamraďová, I., Lipový, B., Holoubek, J., Vacek, L., Růžička, F., Hanslianová, M., Svobodová, T., et al. (2023) · ACS Applied Polymer Materials · doi:10.1021/acsapm.3c00025 · Cited by 42
Li, C., Liu, L., Liang, L., Xia, Z., Li, Z., Wang, X., McGee, L. R., Newhall, K., Sinclair, A. M., Kamb, A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0388 · Cited by 39
“The Ba/F3 cell line is known to be easier to work with for the isolation of mutations resistant to kinase inhibitors (43).”
BackgroundOvercoming resistance to HER2 inhibitors through state-specific kinase binding
Novotny, C. J., Pollari, S., Park, J. H., Lemmon, M. A., Shen, W., & Shokat, K. M. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2171 · Cited by 40
Hudkins, R. L., Allen, E., Balcer, A., Hoffman, I., Iyer, S., Neal, M., Nelson, K. J., Rideout, M., Ye, Q., Starrett, J. H., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01531 · Cited by 38
Investigating human leukemogenesis: from cell lines to in vivo models of human leukemia
Kennedy, J. A., & Barabé, F. (2008) · Leukemia · doi:10.1038/leu.2008.206 · Cited by 50
Nonami, A., Sattler, M., Weisberg, E., Liu, Q., Zhang, J., Patricelli, M. P., Christie, A. L., Saur, A., Kohl, N. E., Kung, A. L., et al. (2015) · Blood · doi:10.1182/blood-2014-12-615906 · Cited by 37
Machado‐Neto, J. A., Fenerich, B. A., Scopim‐Ribeiro, R., Eide, C. A., Coelho‐Silva, J. L., Dechandt, C. R. P., Fernandes, J. C., Alves, A. P. N. R., Scheucher, P. S., Simões, B. P., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0256-4 · Cited by 38
The structure-function relationship of oncogenic LMTK3
Ditsiou, A., Cilibrasi, C., Simigdala, N., Papakyriakou, A., Milton‐Harris, L., Vella, V., Nettleship, J. E., Lo, J. H., Soni, S., Smbatyan, G., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc3099 · Cited by 37
Fragment-Based Discovery of Type I Inhibitors of Maternal Embryonic Leucine Zipper Kinase
Johnson, C. N., Berdini, V., Beke, L., Bonnet, P., Brehmer, D., Coyle, J. E., Day, P. J., Frederickson, M., Freyne, E. J. E., Gilissen, R., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml5001245 · Cited by 39
Dou, D., Wang, J., Qiao, Y., Wumaier, G., Sha, W., Li, W., Mei, W., Yang, T., Zhang, C., He, H., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114856 · Cited by 34
Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge
Ríos-Hoyo, A., Moliner, L., & Arriola, E. (2022) · Cancers · doi:10.3390/cancers14081931 · Cited by 34
Intracellular Delivery of Bioactive Molecules using Light-Addressable Nanocapsules
Gregersen, K. A. D., Hill, Z. B., Gadd, J. C., Fujimoto, B. S., Maly, D. J., & Chiu, D. T. (2010) · ACS Nano · doi:10.1021/nn102345f · Cited by 33
“to determine the intracellular potency of a number of protein kinase inhibitors.(34) Ba/F3 cells expressing the”
BackgroundStructure-Based Design of Type II Inhibitors Applied to Maternal Embryonic Leucine Zipper Kinase
Johnson, C. N., Adelinet, C., Berdini, V., Beke, L., Bonnet, P., Brehmer, D., Calo, F., Coyle, J. E., Day, P. J., Frederickson, M., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml5001273 · Cited by 35
Brown, B. P., Zhang, Y., Kim, S., Finneran, P., Yan, Y., Du, Z., Kim, J., Hartzler, A. L., Lenoue-Newton, M. L., Smith, A. W., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2206588119 · Cited by 33
“To 236 test our hypothesis, we generated expression vectors containing empty vector, WT, E746_A750, 237 E746_S752>V, or L747_A750>P and introduced these into murine lymphoid Ba/F3 cells (43).”
Self-citationMilione, M., Ardini, E., Christiansen, J., Valtorta, E., Veronese, S. M., Bosotti, R., Pellegrinelli, A., Testi, A., Pietrantonio, F., Fucà, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19512 · Cited by 34
“Oncotarget55359www.impactjournals.com/oncotarget Functional studies of SCYL3-NTRK1 fusion gene cDNAs (see supplementary data) encoding the SCYL3-NTRK1 fusion protein was inserted into the lentiviral vector pVL-EF1a-MCS-IRES-Puro (BioSettia, San Diego, CA) and introduced into the murine, IL-3 dependent, pro-B Ba/F3 cel…”
BackgroundMethodInfluentialLee, B. J., & Shah, N. P. (2016) · Leukemia · doi:10.1038/leu.2016.353 · Cited by 31
Guo, Y., Updegraff, B. L., Park, S., Durakoglugil, D., Cruz, V. H., Maddux, S., Hwang, T. H., & O’Donnell, K. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1697 · Cited by 30
Dysregulation of BCL-2 family proteins by leukemia fusion genes
Brown, L. M., Hanna, D. T., Khaw, S. L., & Ekert, P. G. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.799056 · Cited by 33
“The interleukin-3 (IL-3)-dependent cell lines are commonly used to test the capacity of ALL fusions to block apoptosis induced by cytokine deprivation (29).”
BackgroundBanks, E., Grondine, M. R., Bhavsar, D., Barry, E., Kettle, J. G., Reddy, V. P., Brown, C., Wang, H., Mettetal, J. T., Collins, T. A., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz2481 · Cited by 30
“A range of cellular models, including the Ba/F3 cell model (22) expressing the wild type and mutated versions of KIT and PDGFR, was used to profile compounds from the medicinal chemistry effort.”
MethodDecroocq, J., Birsen, R., Montersino, C., Chaskar, P., Mano, J., Poulain, L., Friedrich, C., Alary, A., Guermouche, H., Sahal, A., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01541-0 · Cited by 30
“In activated RAS Ba/F3 cells, a minimal model of oncogene dependency widely employed in drug screening [32], pyrvinium pamoate decreased the viability of IL3-starved NF1 and NRAS cells compared to control cells cultured in the presence of IL-3 (Fig.”
BackgroundShi, X., Sousa, L. P., Mandel-Bausch, E. M., Tomé, F., Reshetnyak, A. V., Hadari, Y. R., Schlessinger, J., & Lax, I. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610179113 · Cited by 30
“These cells are frequently used in kinase drug discovery programs because their IL-3 dependency can be compensated for by expressing oncogenic, constitutively active RTKs in these cells (31).”
BackgroundAn Epigenetic Mechanism Underlying Chromosome 17p Deletion–Driven Tumorigenesis
Chen, M., Chen, X., Li, S., Pan, X., Gong, Y., Zheng, J., Xu, J., Zhao, C., Zhang, Q., Zhang, S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0336 · Cited by 30
“Here, we studied the functions of wildtype PHF23 in Ba/F3 cells, a mouse pro/pre-B cell line(29), by chromatin immunoprecipitation-sequencing (ChIP-seq) assay.”
BackgroundHernandez‐Davies, J. E., Zape, J. P., Landaw, E. M., Tan, X., Presnell, A., Griffith, D., Heinrich, M. C., Glaser, K. B., & Sakamoto, K. M. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0904 · Cited by 29
“Ba/F3 pro-B cells require the presence of interleukin-3 (IL-3) to grow and, without it, undergo rapid apoptosis (20, 21).”
BackgroundA saturation-mutagenesis analysis of the interplay between stability and activation in Ras
Hidalgo, F., Nocka, L. M., Shah, N. H., Gorday, K., Latorraca, N. R., Bandaru, P., Templeton, S., Lee, D., Karandur, D., Pelton, J. G., et al. (2022) · eLife · doi:10.7554/elife.76595 · Cited by 28
“The murine Ba/F3 hematopoietic cell line is dependent on the cytokine interleukin- 3 (IL3) for growth, but the IL- 3 dependence can be bypassed by the expression of activated variants of tyrosine kinases, such as BCR- Abl (Daley and Baltimore, 1988; Mandanas et al., 1993; Warmuth et al., 2007).”
The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug
Teng, M., Luskin, M. R., Cowan‐Jacob, S. W., Ding, Q., Fabbro, D., & Gray, N. S. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00373 · Cited by 29
Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor
Bhattacharjee, D., Bakar, J., Chitnis, S. P., Sausville, E. L., Ashtekar, K. D., Mendelson, B. E., Long, K., Smith, J. C., Heppner, D. E., & Sheltzer, J. M. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.09.013 · Cited by 30
Wei, L., & Malhotra, S. V. (2012) · MedChemComm · doi:10.1039/c2md20097j · Cited by 28
Xu, D., Sun, D., Wang, W., Peng, X., Zhan, Z., Ji, Y., Shen, Y., Geng, M., Ai, J., & Duan, W. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113497 · Cited by 27
A functional genomic approach to actionable gene fusions for precision oncology
Li, J., Lu, H., Ng, P. K., Pantazi, A., Ip, C. K. M., Jeong, K. J., Amador, B. E., Tran, R., Tsang, Y. H., Yang, L., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm2382 · Cited by 28
“Ba/F3 is a murine pro-B cell line that depends on interleukin-3 (IL-3) for growth and proliferation but can be readily transformed to IL-3 independence in the presence of an oncogenic event, thereby making it widely used for detecting oncogenic events (14).”
BackgroundSmall molecule tyrosine kinase inhibitors and pancreatic cancer—Trials and troubles
Bhaskar, L. V., Farran, B., Lakkakula, S., Peela, S., Yarla, N. S., Bramhachari, P. V., Kamal, M. A., Saddala, M. S., & Nagaraju, G. P. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.09.011 · Cited by 27
An unbiased in vitro screen for activating epidermal growth factor receptor mutations
Chakroborty, D., Kurppa, K. J., Paatero, I., Ojala, V. K., Koivu, M. K. A., Tamirat, M. Z., Koivunen, J. P., Janne, P. A., Johnson, M. S., Elo, L. L., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006336 · Cited by 28
“Moreover, the fact that the Ba/F3 cells have been widely used for addressing the functional activation of several receptor as well as nonreceptor tyrosine kinases (8) indicates that the same Ba/F3-based pipeline could be used for analyzing a number of kinases in addition to EGFR.”
BackgroundMathison, C. J. N., CHIANELLI, D., Rucker, P. V., Nelson, J. T., Roland, J. T., Huang, Z., Yang, Y., Jiang, J., Xie, Y. F., Epple, R., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00015 · Cited by 26
Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings
Yu, V. L., Pistillo, J., Archibeque, I., Lee, J. H., Sun, B.-C., Schenkel, L. B., Geuns-Meyer, S. D., Liu, L., & Emkey, R. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.01.005 · Cited by 25
“a valid functional endpoint for JAK activity [25,26].”
BackgroundRoa, P., Foglizzo, V., Harada, G., Repetto, M., Kulick, A. R., de Stanchina, E., de Marchena, M., Auwardt, S. L., Ahmed, S. S., Bremer, N. V., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02760-1 · Cited by 25
“4).”
Gebreyohannes, Y. K., Burton, E. A., Woźniak, A., Matusow, B., Habets, G. G. M., Wellens, J., Cornillie, J., Lin, J. Y.-S., Nespi, M., Wu, G., et al. (2018) · Clinical and Experimental Medicine · doi:10.1007/s10238-018-0541-2 · Cited by 24
Mus, L. M., Lambertz, I., Claeys, S., Kumps, C., Loocke, W. V., Neste, C. V., Umapathy, G., Vaapil, M., Bartenhagen, C., Laureys, G., et al. (2020) · Scientific Reports · doi:10.1038/s41598-019-57076-5 · Cited by 26
Metadata
- Authors
- Warmuth, M., Kim, S., Gu, X.-J., Xia, G., & Adrián, F.
- Affiliations
- Genomics Institute of the Novartis Research Foundation (US)
- Corresponding author
- Warmuth, Markus
- ORCID
- Xia, Gang
- Venue
- Current Opinion in Oncology
- Published
- 2007-01
- Volume
- 19
- Issue
- 1
- Pages
- 55-60
- ISSN
- 1040-8746 (ISSN-L)
- OpenAlex
- W2088757697
- Cited by
- 240
- References
- 60
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 27 · 2023: 22 · 2022: 25 · 2021: 19 · 2020: 18 · 2019: 5 · 2018: 13 · 2017: 14 · 2016: 14 · 2015: 9 · 2014: 11 · 2013: 10 · 2012: 7
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- Ba/F3 cells, protein kinases, kinase inhibitors, kinase drug discovery, oncogenes, small-molecule kinase inhibitors, high-throughput screening, compound profiling, drug resistance prediction, point mutations, downstream signaling, interleukin-3 dependence
- MeSH terms
- Animals, Antineoplastic Agents, Cell Line, Cell Transformation, Neoplastic, Epidermal Growth Factor, Drug Design, Signal Transduction, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Mice, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.